MCM
BIO icon

MAI Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

MAI Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Buy
801
+646
+417% +$183K ﹤0.01% 1726
2026
Q1 		$43.2K Buy
155
+52
+50% +$15K ﹤0.01% 2321
2025
Q4 		$31.2K Buy
103
+70
+212% +$21.8K ﹤0.01% 2279
2025
Q3 		$9.25K Sell
33
-13
-28% -$3.54K ﹤0.01% 2776
2025
Q2 		$11.1K Buy
46
+32
+229% +$7.57K ﹤0.01% 2672
2025
Q1 		$3.41K Sell
14
-7
-33% -$2.11K ﹤0.01% 2840
2024
Q4 		$6.9K Buy
+21
New +$7.13K ﹤0.01% 2659

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

MAI Capital Management's BIO Position: Q2 2026 in Review

MAI Capital Management increased its Bio-Rad Laboratories Class A (BIO) stake by 417% in Q2 2026, buying an estimated $183K and bringing the position to 801 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

MAI Capital Management first reported a position in BIO in Q4 2024 and has held it in 7 quarters since. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • MAI Capital Management held 801 shares of Bio-Rad Laboratories Class A worth $235K as of Q2 2026.
  • MAI Capital Management bought 646 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $183K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1726 holding.
  • MAI Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and has held it in 7 quarters since.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.